Mass tort litigation changed on three fronts this quarter: the Supreme Court cut down Roundup failure-to-warn claims, Johnson & Johnson agreed to pay $5.5 billion to settle roughly 76,000 ovarian-cancer talc claims, and Pfizer reached an agreement in principle on Depo-Provera meningioma cases. The practical effect for anyone holding a claim is that two of the largest dockets moved toward resolution while a third — Roundup — now turns on whether design-defect theories survive federal preemption.
A mass tort is a group of individual injury lawsuits over the same product, consolidated before one federal judge in a multidistrict litigation, or MDL, for shared pretrial work. Each case keeps its own facts and its own damages, which is what separates it from a class action. That distinction matters more than usual right now, because the September developments below affect classes of claims, not every claimant equally.
Table of Contents
- How big is the federal mass tort docket, really?
- The Roundup ruling and the fight over what it covers
- The $5.5 billion talc settlement and why the docket has not shrunk
- What moved in the other large dockets
- Social media litigation reaches trial
- Two rule changes worth tracking
- Frequently Asked Questions
How big is the federal mass tort docket, really?
The Judicial Panel on Multidistrict Litigation counted 166 pending MDL dockets holding 206,182 actions in its September 1, 2026 pending-dockets report. Twenty-one of those dockets hold 1,000 or more cases each, and together they account for 194,835 actions — 94.5% of the total. Forty dockets hold fewer than ten cases apiece.
The federal civil system's consolidated caseload is therefore concentrated in a handful of product litigations, and the pace of those few determines how long most claimants wait. For a reader with a pending claim, this concentration is the reason individual cases move slowly. A judge managing 69,000 filings runs bellwether trials — test cases chosen to show both sides how juries value the evidence — rather than trying cases in filing order.
The Roundup ruling and the fight over what it covers
On June 25, 2026, the Supreme Court held 7–2 in *Monsanto Co. v. Durnell* that the Federal Insecticide, Fungicide, and Rodenticide Act expressly preempts a state-law failure-to-warn claim that would require a cancer warning on Roundup's EPA-approved label. Justice Kavanaugh wrote the majority; Justices Jackson and Gorsuch dissented. The opinion in No.
24-1068 turns on labeling: a state cannot demand wording the federal regulator did not approve. Bayer has since moved Judge Vince Chhabria to dismiss the roughly 3,900 cases remaining in Roundup MDL 2741, arguing they are failure-to-warn claims repackaged under other names. Plaintiffs counter that design-defect and negligence theories do not depend on the label and survive *Durnell*. No final ruling has issued. That unresolved motion is the single most consequential pending decision in mass torts this fall. If the court reads *Durnell* broadly, the federal Roundup docket largely ends; if narrowly, thousands of claims continue on non-labeling theories.
The $5.5 billion talc settlement and why the docket has not shrunk
Johnson & Johnson announced on July 27, 2026 a $5.5 billion settlement covering approximately 76,000 ovarian-cancer talc claims. The company disclosed the agreement in an exhibit to a Form 8-K filed with the SEC. It followed an MDL ruling on specific causation — the question of whether talc caused a particular plaintiff's cancer — and the withdrawal of two plaintiff experts.
The deal is not yet final. Talc MDL 2738 still showed 69,250 pending federal actions on September 1, 2026, according to the same JPML report. An announced settlement does not clear a docket: participation has to be solicited, eligibility documented, and claims processed, and cases sit on the court's list throughout. Practical consequences for a talc claimant:.
- An announcement is not a payment. Terms, allocation, and participation thresholds govern what any individual receives.
- Medical records and product-use proof drive value in every settlement of this type; gather them before a deadline is set, not after.
- Filing has not stopped, and neither has the claims work that precedes any distribution.
What moved in the other large dockets
Pfizer and plaintiffs' lead counsel reached a global agreement in principle resolving eligible Depo-Provera meningioma claims, about 3,400 cases. Judge M. Casey Rodgers vacated deadlines for the December 7, 2026 *Blonski* bellwether in a June 15, 2026 order, posted on the Northern District of Florida's MDL 3140 page. Terms remain undisclosed. A federal jury in the District of Arizona awarded Kimberly Divelbliss $40 million in compensatory damages on September 10, 2026, on design-defect and failure-to-warn claims, after her Bard PowerPort catheter fractured and a fragment lodged in her heart.
The jury declined punitive damages. That verdict is a bellwether in MDL 3081, meaning it signals settlement value rather than binding other plaintiffs. The AFFF firefighting-foam litigation, MDL 2873, held 15,264 personal-injury claims in September 2026 with no bellwether trial date on the calendar. Judge Richard Gergel is assembling a second pool of 28 drinking-water cases — 8 kidney cancer, 8 testicular cancer, 8 thyroid disease, and 4 ulcerative colitis. A claimant whose injury is not among those four categories should expect a longer wait, because the pool defines which injuries get tested first.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
Social media litigation reaches trial
The 29-state attorneys general case against Meta opened before Judge Yvonne Gonzalez Rogers in Oakland on August 18, 2026. It runs alongside 3,137 personal-injury actions in MDL 3047, the adolescent social-media addiction litigation. The first private trial, *K.G.M. v.
Meta & YouTube*, produced a $6 million verdict in Los Angeles on March 25, 2026. That verdict is on appeal, so it establishes no settled law yet. Two different tracks are running here, and they pay out differently. The attorneys general case seeks state remedies and penalties; the MDL cases seek damages for individual minors and families. A parent following the AG trial for news of a payout is watching the wrong docket.
Two rule changes worth tracking
Federal Rule of Civil Procedure 16.1 took effect December 1, 2025. It is the first federal rule written specifically for MDL practice, and it structures how judges hold initial management conferences in consolidated proceedings — the point at which leadership, discovery scope, and case schedules get set. The Advisory Committee on Civil Rules meets October 21, 2026 on a draft rule requiring disclosure of third-party litigation funding agreements to the parties.
In September 2026, 214 companies urged its adoption, as reported by Unified Patents on September 14, 2026. Litigation funding is outside capital that pays a case's costs in exchange for a share of any recovery, and it underwrites much of the advertising that recruits mass tort claimants. Disclosure would not ban funding. It would make the funder visible to opposing counsel and the court, which changes settlement negotiations in dockets where thousands of claims were assembled with outside money.
Frequently Asked Questions
Does the Supreme Court's Roundup decision end every Roundup case?
No. It preempts state failure-to-warn claims that would require a cancer warning on the EPA-approved label. Whether design-defect and negligence claims survive is the question now before Judge Chhabria in MDL 2741, and about 3,900 cases are pending on that answer.
Why is talc MDL 2738 still showing 69,250 cases after a settlement was announced?
The announced deal is not final, and settlements do not remove cases from a court's docket on announcement. Claims must be solicited, documented, and processed before dismissals are entered.
Does a $40 million bellwether verdict mean other plaintiffs get $40 million?
No. A bellwether is a test case tried on its own facts. Its value informs settlement talks across the MDL, but it binds no other plaintiff, and the Divelbliss jury declined punitive damages.
What does it mean that AFFF has no trial date?
MDL 2873's 15,264 personal-injury claims are waiting while Judge Gergel builds a second bellwether pool of 28 drinking-water cases limited to kidney cancer, testicular cancer, thyroid disease, and ulcerative colitis.
You Might Also Like
- Verdicts Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Medical Device Lawsuits Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next
- Legal Glossary Mass Tort Litigation September 2026 Update: What Changed, Why It Matters, and What to Watch Next